NCT05978544View on ClinicalTrials.gov

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

Itolizumab

Patients to be treated with Itolizumab.

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER